Company Overview

Aspira Women’s Health Inc. is a U.S.-based healthcare and biotechnology company focused on gynecologic disease diagnostics and women’s health risk assessment. The company operates primarily in the molecular diagnostics and women’s healthcare industries, with an emphasis on ovarian cancer risk evaluation, pelvic mass assessment, and the development of noninvasive diagnostic tools. Aspira’s core commercial offerings include the OVA1 and OVERA blood tests, which are designed to help physicians assess the likelihood of ovarian malignancy in women presenting with an adnexal mass prior to surgery. The company also markets risk assessment and patient management technologies associated with gynecologic care.

The company’s principal revenue drivers are diagnostic testing services, laboratory processing, and related clinical support services. Aspira primarily serves obstetricians, gynecologists, gynecologic oncologists, hospitals, and healthcare systems in the United States. The company positions itself around the unmet need for earlier and more accurate detection of ovarian cancer, leveraging biomarker-based algorithms and proprietary testing platforms. Originally founded as Vermillion, Inc., the company later rebranded to Aspira Women’s Health Inc. to reflect a broader strategic focus on women’s health diagnostics and decentralized risk assessment technologies.

Business Operations

Aspira Women’s Health conducts operations primarily through its diagnostic testing and laboratory services platform. The company’s commercial business centers on the OVA1, OVERA, and related ovarian cancer risk assessment products, which are processed through its certified laboratory infrastructure. Revenue is generated through test sales reimbursed by insurers, healthcare providers, and patients, as well as through clinical partnerships and service agreements. The company has historically focused on the U.S. market, where its products are integrated into physician referral networks and hospital systems.

The company controls proprietary biomarker algorithms, clinical data assets, and intellectual property related to ovarian cancer diagnostics and gynecologic disease assessment. Aspira has also invested in data-driven healthcare technologies intended to support longitudinal patient monitoring and personalized risk stratification. Strategic collaborations have included relationships with diagnostic laboratories, clinical institutions, and healthcare distribution partners. Public filings and company disclosures reference operational emphasis on laboratory optimization, reimbursement expansion, and broader adoption among OB/GYN providers.

Strategic Position & Investments

Aspira Women’s Health has positioned itself as a specialized diagnostics company targeting gaps in women’s health, particularly ovarian cancer detection and disease management. Its strategic direction has emphasized expanding adoption of existing diagnostic products while advancing additional biomarker-based technologies for gynecologic conditions. The company has invested in research and development initiatives involving artificial intelligence-assisted risk assessment, protein biomarker analysis, and longitudinal patient data integration intended to improve diagnostic precision and clinical workflow support.

The company has also pursued acquisitions and portfolio expansion initiatives tied to women’s health technology assets. Public disclosures reference investments in decentralized diagnostic models and digital health capabilities aimed at improving patient engagement and disease monitoring. Aspira’s broader strategy has included strengthening reimbursement coverage, increasing physician utilization, and leveraging clinical evidence to support guideline inclusion and payer acceptance. Data regarding long-term commercial scalability remains dependent on future adoption rates and financing capacity disclosed in public filings.

Geographic Footprint

Aspira Women’s Health is headquartered in Austin, Texas, and conducts the majority of its commercial operations within the United States. Its laboratory and diagnostic service activities are primarily focused on the domestic healthcare market, including physician offices, hospitals, and specialized women’s health providers. The company’s products are marketed nationally through direct and partner-supported commercial channels.

While the company’s operational footprint is predominantly U.S.-based, its technologies and intellectual property have relevance to broader international women’s health markets. Publicly available information indicates limited direct international commercial operations compared with larger multinational diagnostics firms. Data inconclusive based on available public sources regarding substantial overseas revenue contribution or material foreign operating infrastructure.

Leadership & Governance

Aspira Women’s Health operates under a corporate governance structure led by executive management and a board of directors responsible for strategic oversight, capital allocation, and operational execution. The company’s leadership has emphasized expanding access to women’s health diagnostics, advancing biomarker science, and improving earlier detection pathways for ovarian cancer and related gynecologic diseases. Strategic communications and public filings indicate a focus on disciplined commercialization, clinical validation, and operational efficiency.

Key executives identified in recent public filings and corporate disclosures include:

• Nicole Sandford – Chief Executive Officer
• Michael Buhle – Chief Financial Officer
• Lori M. Smego – Chief Medical Officer
• Leslie Trigg – Former Chief Executive Officer and strategic advisor roles referenced in prior filings

Leadership composition and executive responsibilities may change over time based on board actions and subsequent corporate disclosures filed with the SEC.